Gosta Labs Raises €7.5M To Scale AI Platform For Oncology

The round was led by Voima Ventures, with participation from COR Group, the Aho family, and both existing and new investors, including Reaktor and notable angels. Following a €1.7 million pre-seed round in 2024 the company’s total funding now approaches €10 million.

Cancer care is becoming increasingly complex. Studies project over 35 million new cancer cases by 2050 across more than 100 cancer types. Clinicians spend several hours daily on administrative tasks within fragmented systems containing largely unstructured clinical data, while multidisciplinary teams must make rapid, high-stakes decisions across an expanding range of personalized treatments.

Read Also- Polish HRTech Startup Global Work AI Raises €2M To Boost AI Job Tools And Launch Career Assistant

Gosta Labs addresses these challenges with an oncology-focused AI operating system that converts each patient visit into high-quality structured data in real time. The system summarizes and visualizes patient journeys, automates clinical documentation, and captures structured clinical data critical to patient care.

It also enhances quality of care by assessing key clinical parameters for each treatment pathway and automatically linking decisions to international guidelines, helping oncologists deliver faster, more consistent care.

Initial real-world results, presented at the ESMO 2025 Congress, show that the Gosta AI Operating System produces high-quality consultation notes in real time, structured according to institutional standards. The system automatically classifies Performance Status and CTCAE toxicity grades, enabling oncologists to complete follow-up visit documentation in a median time of under two minutes, significantly reducing administrative workload and allowing more time for direct patient care.

“We started Gosta Labs to bring AI to support extremely complex medical specialties like oncology, to give care teams back time and headspace for their patients by taking on the documentation work that drains their day,” said Lauri Sippola, CEO and Co Founder of Gosta Labs. “This funding helps us bring our trusted AI assistant to oncology teams around the world and deepen our medical device grade product and AI foundation, so every patient encounter can be safer, more personal, and less burdened by administration.”

Founded in 2023 by Lauri Sippola and Henri Viertolahti, the founders of Kaiku Health (acquired by Elekta in 2020) Gosta Labs leverages a proven track record in developing and scaling regulated digital health solutions globally. The team combines AI specialists with experienced oncology and medtech leaders, including Chief Medical Officer Dr. Lionel Hadjadjeba and Chief Operating Officer Reetta Arokoski, both of whom have extensive experience scaling cancer care technologies internationally.

The new funding will be used to expand the reach of Gosta Labs’ AI assistant to oncology teams worldwide and to further strengthen its medical-device-grade product and AI infrastructure, enabling safer, more personalized patient care while reducing administrative burdens.

About Gosta Labs

Gosta Labs is building Europe’s leading AI lab for healthcare, specializing in machine learning models that improve efficiency and patient outcomes. As an AI science company it develops safe, regulatory-compliant solutions with excellent user experience, driven by a mission to enhance healthcare through evidence-based artificial intelligence.